Logo image of ASBP

ASPIRE BIOPHARMA HOLDINGS IN (ASBP) Stock Fundamental Analysis

NASDAQ:ASBP - Nasdaq - US7389201077 - Common Stock - Currency: USD

0.3401  -0.02 (-5.26%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ASBP. ASBP was compared to 198 industry peers in the Pharmaceuticals industry. ASBP has a bad profitability rating. Also its financial health evaluation is rather negative. ASBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ASBP has reported negative net income.
In the past year ASBP has reported a negative cash flow from operations.
ASBP Yearly Net Income VS EBIT VS OCF VS FCFASBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2022 2023 2024 0 -5M -10M

1.2 Ratios

ASBP has a Return On Assets of -182.56%. This is amonst the worse of the industry: ASBP underperforms 86.36% of its industry peers.
With a Return On Equity value of -1998.64%, ASBP is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -182.56%
ROE -1998.64%
ROIC N/A
ROA(3y)-54.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASBP Yearly ROA, ROE, ROICASBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2022 2023 2024 0 100 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASBP Yearly Profit, Operating, Gross MarginsASBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ASBP has been reduced compared to 1 year ago.
Compared to 1 year ago, ASBP has a worse debt to assets ratio.
ASBP Yearly Shares OutstandingASBP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
ASBP Yearly Total Debt VS Total AssetsASBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.84, we must say that ASBP is in the distress zone and has some risk of bankruptcy.
ASBP has a Altman-Z score of -3.84. This is in the lower half of the industry: ASBP underperforms 60.10% of its industry peers.
ASBP has a Debt/Equity ratio of 8.54. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 8.54, ASBP is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 8.54
Debt/FCF N/A
Altman-Z -3.84
ROIC/WACCN/A
WACCN/A
ASBP Yearly LT Debt VS Equity VS FCFASBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

ASBP has a Current Ratio of 0.05. This is a bad value and indicates that ASBP is not financially healthy enough and could expect problems in meeting its short term obligations.
ASBP has a worse Current ratio (0.05) than 96.46% of its industry peers.
A Quick Ratio of 0.05 indicates that ASBP may have some problems paying its short term obligations.
With a Quick ratio value of 0.05, ASBP is not doing good in the industry: 96.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ASBP Yearly Current Assets VS Current LiabilitesASBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

ASBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1194.69%.
EPS 1Y (TTM)-1194.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6668.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ASBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASBP Price Earnings VS Forward Price EarningsASBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASBP Per share dataASBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ASBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASPIRE BIOPHARMA HOLDINGS IN

NASDAQ:ASBP (5/2/2025, 3:51:09 PM)

0.3401

-0.02 (-5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners6.09%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.63M
AnalystsN/A
Price TargetN/A
Short Float %0.47%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.51
P/tB 26.51
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.56%
ROE -1998.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 8.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -3.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1194.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6668.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-131.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-214.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-214.61%
OCF growth 3YN/A
OCF growth 5YN/A